Our Technology
The promise of circulating cell-free DNA (cfDNA) as a biomarker for cancer treatment has yet to be fully realized. Technology from Salish Bioscience utilizes groundbreaking molecular biology to address the unmet need for greater sensitivity in cancer diagnostics.
these innovations result in our
core strengths:
Depth
Greater depth improves the sensitivity of critical variant detection
Uniformity
Consistent coverage across targeted regions
Bioinformatics
Sampling technology that facilitates bioinformatics analysis
Flexibility
Rapid development of custom targeting panels
Depth
The liquid biopsy process utilized at Salish Bioscience results in an increase in fragment depth (our ability to detect circulating tumor DNA fragments (ctDNA) at very low mutant allele frequencies) across all targeted regions compared to currently available technologies. This enables higher levels of diagnostic sensitivity.
Uniformity
Uniform depth of coverage across all genomic targets provides reliable assay output over a broad spectrum of medically important regions. Our technology enables the assessment of mutations within different regions on a consistent basis.
Bioinformatics
Sample preparation has been designed to inform and integrate with downstream bioinformatics analysis. Our proprietary bioinformatics process is able to identify single nucleotide variants, short indels, chromosomal rearrangements, copy number variation, and methylation status.
Flexibility
Our platform lends itself to customizable panels to fit individual patient needs. We specialize in state-of-the-art Precision Medicine diagnostics as well as tumor-informed Minimal Residual Disease monitoring.
